Foresight Diagnostics' PhasED-Seq ctDNA detection enables accurate treatment response monitoring and clinical prognosis in patients with B-cell lymphomas.
Saturday, Dec 10, 2022 @4:45 PM CT | session 627, Theater AB
Mark Roschewski, MD, of the National Cancer Institute will present data showing that PhasED-Seq's sensitivity exceeded that of PET/CT scans and was highly prognostic for outcomes when used to measure MRD at the end of treatment in 5 clinical trials of patients with DLBCL.Download the Abstracts
Saturday, Dec 10, 2022 @5:30 - 7:30 PM CT | session 621, Hall D
David M. Kurtz, MD PhD, of the Stanford University School of Medicine has authored a poster presenting data on the use of PhasED-Seq to accurately track therapeutic response and predict clinical outcomes of first line therapy combinations in de novo DLBCL.Download the Abstracts
monday, Dec 12, 2022 @5:45 PM CT | session 704, Hall E
Dr. Kurtz gives an oral presentation of data from the CHARIOT phase 2 clinical trial that supports PhasED-Seq ctDNA detection as a viable biomarker to assess risk, monitor response, and predict outcomes in patients with recurrent classic Hodgkin Lymphoma treated with CD30.CAR-T therapy.Download the Abstracts
“We are very pleased to have been selected by ASH to share these impactful clinical studies utilizing Foresight's PhasED-Seq MRD technology for guiding lymphoma treatments and furthering clinical trials. Our goal is to provide industry leading MRD sensitivity that can provide actionable information to physicians and pharmaceutical companies to enhance a personalized approach to cancer treatment.”
Jake Chabon, PhD
CEO and Co-Founder of Foresight Diagnostics
Interested in meeting up?
Request a meeting with the Foresight team